InvestSMART

Archer Materials Limited (ASX: AXE) - Announcements

Current share price for AXE : $0.180 0.01 (5.26%)+

ASX company news and announcements for Archer Materials Limited (AXE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Archer Materials Limited (AXE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Archer Materials Limited (AXE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Archer Materials Limited (AXE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$51 Notification of cessation of securities - AXE 2 Jun 2025 8:26AM $0.300 $0.180 fallen by 40%
$51 Biochip integrates with readout circuitry on a silicon chip 29 May 2025 8:59AM $0.295 $0.180 fallen by 38.98%
$51 Archer partners with Paragraf for Biochip development 19 May 2025 9:23AM $0.250 $0.180 fallen by 28%
$51 Partnership extended with QMUL 12 May 2025 9:30AM $0.265 $0.180 fallen by 32.08%
$51 Presentation - Semiconductor Conference 2025 7 May 2025 8:22AM $0.275 $0.180 fallen by 34.55%
$51 Appointment of Company Secretary 5 May 2025 8:40AM $0.270 $0.180 fallen by 33.33%
$51 Quarterly Activity Report & Appendix 4C 16 Apr 2025 8:20AM $0.260 $0.180 fallen by 30.77%
$51 12CQ Quantum Program Presentation- RMIT Quantum Industry Day 9 Apr 2025 10:08AM $0.245 $0.180 fallen by 26.53%
$51 AXE partners with Hylid Diagnostics for Biochip development 31 Mar 2025 9:11AM $0.300 $0.180 fallen by 40%
$51 Appointment of Chief Executive Officer 27 Mar 2025 8:50AM $0.300 $0.180 fallen by 40%
$51 Appendix 4D and Half Year Financial Report 26 Feb 2025 12:03PM $0.325 $0.180 fallen by 44.62%
$51 Improved Biochip Accuracy Paves Way for Human Blood Testing 25 Feb 2025 9:05AM $0.330 $0.180 fallen by 45.45%
$51 Precision spin state control for next-generation qubits 13 Feb 2025 9:41AM $0.355 $0.180 fallen by 49.30%
$51 Archer Granted Key Biochip Patent 22 Jan 2025 9:32AM $0.430 $0.180 fallen by 58.14%
$51 Quarterly Activity Report & Appendix 4C 17 Jan 2025 9:46AM $0.415 $0.180 fallen by 56.63%
$51 Breakthrough in Quantum Carbon Films for Qubit Realisation 8 Jan 2025 9:17AM $0.455 $0.180 fallen by 60.44%
$51 Response to ASX Price Query Letter 16 Dec 2024 1:12PM $0.385 $0.180 fallen by 53.25%
$51 Change in substantial holding for CMX 2 Dec 2024 9:20AM $0.315 $0.180 fallen by 42.86%
$51 Biochip moves toward feasibility & improved testing accuracy 28 Nov 2024 10:01AM $0.300 $0.180 fallen by 40%
$51 Archer receives $2.1 million R&D Tax Incentive rebate 27 Nov 2024 9:07AM $0.300 $0.180 fallen by 40%
$51 Archer receives prototype TMR sensors from foundry partner 25 Nov 2024 9:46AM $0.290 $0.180 fallen by 37.93%
$51 Change of Director's Interest Notice x 3 20 Nov 2024 4:43PM $0.305 $0.180 fallen by 40.98%
$51 Notification regarding unquoted securities - AXE 20 Nov 2024 4:41PM $0.305 $0.180 fallen by 40.98%
$51 Notification regarding unquoted securities - AXE 20 Nov 2024 4:31PM $0.305 $0.180 fallen by 40.98%
$51 Notification of cessation of securities - AXE 20 Nov 2024 4:23PM $0.305 $0.180 fallen by 40.98%

76 - 100 of 931 results

Page 4 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.